文献速递炎症性肠病

抗整合素αvβ6自身抗体是一种先于溃疡性结肠炎出现的新型生物标志物

Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis.
PubMed 文献 · Gastroenterology · 2023-01-10

在PREDICTS队列中,抗整合素αvβ6自身抗体在溃疡性结肠炎(UC)诊断前10年即可检出,阳性率从诊断前10年的12.2%升至诊断时的52.4%,对照组为2.7%;该抗体预测UC发生的曲线下面积至少为0.8,并在GEM队列中得到验证;高抗体水平与新诊断UC的不良结局复合终点相关。

要点

  • 抗整合素αvβ6自身抗体可在UC临床诊断前长达10年出现,预测UC发生的曲线下面积至少为0.8。
  • PREDICTS队列中,UC患者诊断前10年抗体阳性率为12.2%,诊断时升至52.4%,对照组4个时间点均为2.7%。
  • 在新诊断UC中,高抗整合素αvβ6自身抗体与住院、疾病扩展、结肠切除、全身激素使用和/或升级生物制剂治疗的复合不良结局相关。

核心结论

  • 抗整合素αvβ6自身抗体先于UC临床诊断长达10年出现,并与UC相关不良结局相关。

研究设计与样本

  • 研究在PREDICTS队列82例日后发生UC者与82例匹配对照的4份纵向血清样本中检测抗整合素αvβ6自身抗体。
  • 在外部队列GEM中检测12例UC前个体与49例匹配对照。
  • 在COMPASS队列55例和OSCCAR队列104例新诊断UC中检测抗体,并用Cox比例风险模型分析其与UC相关结局的关联。

主要发现

  • 在PREDICTS中,日后发生UC者诊断前10年内抗整合素αvβ6自身抗体显著高于对照。
  • UC患者抗整合素αvβ6自身抗体阳性率在诊断前10年为12.2%,诊断时升至52.4%,对照在4个时间点为2.7%。
  • 抗整合素αvβ6自身抗体预测UC发生的曲线下面积在诊断前10年至少为0.8。
  • UC前样本中抗整合素αvβ6自身抗体的存在在GEM队列中得到验证。
  • 在新诊断UC中,高抗整合素αvβ6自身抗体与住院、疾病扩展、结肠切除、全身激素使用和/或升级生物制剂治疗的复合不良结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. Anti-integrin αvβ6 (anti-αvβ6) autoantibodies have been described in patients with UC. We tested for the presence of anti-αvβ6 antibodies in the preclinical phase of UC and studied their association with disease-related outcomes after diagnosis. METHODS: Anti-αvβ6 autoantibodies were measured in 4 longitudinal serum samples collected from 82 subjects who later developed UC and 82 matched controls from a Department of Defense preclinical cohort (PREDICTS [Proteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects]). In a distinct, external validation cohort (Crohn's and Colitis Canada Genetic Environmental Microbial project cohort), we tested 12 pre-UC subjects and 49 matched controls. Furthermore, anti-αvβ6 autoantibodies were measured in 2 incident UC cohorts (COMPASS [Comprehensive Care for the Recently Diagnosed IBD Patients], n = 55 and OSCCAR [Ocean State Crohn's and Colitis Area Registry], n = 104) and associations between anti-αvβ6 autoantibodies and UC-related outcomes were defined using Cox proportional hazards model. RESULTS: Anti-αvβ6 autoantibodies were significantly higher among individuals who developed UC compared with controls up to 10 years before diagnosis in PREDICTS. The anti-αvβ6 autoantibody seropositivity was 12.2% 10 years before diagnosis and increased to 52.4% at the time of diagnosis in subjects who developed UC compared with 2.7% in controls across the 4 time points. Anti-αvβ6 autoantibodies predicted UC development with an area under the curve of at least 0.8 up to 10 years before diagnosis. The presence of anti-αvβ6 autoantibodies in preclinical UC samples was validated in the GEM cohort. Finally, high anti-αvβ6 autoantibodies was associated with a composite of adverse UC outcomes, including hospitalization, disease extension, colectomy, systemic steroid use, and/or escalation to biologic therapy in recently diagnosed UC. CONCLUSIONS: Anti-integrin αvβ6 autoantibodies precede the clinical diagnosis of UC by up to 10 years and are associated with adverse UC-related outcomes.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Livanos AE, Dunn A, Fischer J, et al. Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. Gastroenterology. 2023. PMID: 36634824. doi:10.1053/j.gastro.2022.12.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。